The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Identification Of Biomarkers Predictive Of Response To Bevacizumab In Patients With Glioblastoma Multiforme
Funder
National Health and Medical Research Council
Funding Amount
$32,628.00
Summary
Despite multimodality therapy, the median survival for patients diagnosed with high grade malignant brain tumours is only 12 months. Patient response to therapy is highly variable. Our aim is to develop a “genetic signature” that will predict response to bevacuzimab (an agent targeting blood vessel formation). Identifying patients who will respond to bevacuzimab will save many patients from a toxic and costly therapy, from which they will derive little benefit.
Individualisation Of Immunosuppressant Therapy In Renal Transplant Recipients.
Funder
National Health and Medical Research Council
Funding Amount
$113,496.00
Summary
People who undergo kidney transplantation require potent anti-rejection medications. Dosing is difficult. Two people given the same drug dose can have markedly different blood drug concentrations. If drug concentrations too low, there is an increased risk of rejection. If too high, there is an increased risk of drug side effects, infections and cancer. This study aims to find out why different people need different doses and to improve dosing methods, thereby improving patient outcomes.